-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 25, Zhejiang Puli Pharmaceutical submitted a clinical application for the new drug category 2 of Memantine Hydrochloride Granul.
Memantine is a best-selling anti-dementia drug for the nervous syst.
Currently, there are capsules, tablets, and oral liquids on the mark.
No granules have been approved for marketing or import.
Memantine is a best-selling anti-dementia drug for the nervous syst.
Currently, there are capsules, tablets, and oral liquids on the mark.
No granules have been approved for marketing or import.
Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's dement.
According to data from Min.
com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
According to data from Min.
com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
Figure 1: 2021 Memantine Sales Percentage in Various End Markets
Source: Mi intranet database
The terminals of public medical institutions in China are the main battlefield of Memanti.
Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
Table 1: Improved new drugs declared by Zhejiang Puli Pharmaceutical since 2020
Source: MED0 China Drug Evaluation Database
Levetiracetam granules are Puli's first improved new drug to be declared for marketi.
At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
Source: CDE official website, Minet database
On May 25, Zhejiang Puli Pharmaceutical submitted a clinical application for the new drug category 2 of Memantine Hydrochloride Granul.
Memantine is a best-selling anti-dementia drug for the nervous syst.
Currently, there are capsules, tablets, and oral liquids on the mark.
No granules have been approved for marketing or import.
Memantine is a best-selling anti-dementia drug for the nervous syst.
Currently, there are capsules, tablets, and oral liquids on the mark.
No granules have been approved for marketing or import.
Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's dement.
According to data from Min.
com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
According to data from Min.
com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
Figure 1: 2021 Memantine Sales Percentage in Various End Markets
Source: Mi intranet database
The terminals of public medical institutions in China are the main battlefield of Memanti.
Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
Table 1: Improved new drugs declared by Zhejiang Puli Pharmaceutical since 2020
Source: MED0 China Drug Evaluation Database
Levetiracetam granules are Puli's first improved new drug to be declared for marketi.
At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
Source: CDE official website, Minet database
On May 25, Zhejiang Puli Pharmaceutical submitted a clinical application for the new drug category 2 of Memantine Hydrochloride Granul.
Memantine is a best-selling anti-dementia drug for the nervous syst.
Currently, there are capsules, tablets, and oral liquids on the mark.
No granules have been approved for marketing or import.
Memantine is a best-selling anti-dementia drug for the nervous syst.
Currently, there are capsules, tablets, and oral liquids on the mark.
No granules have been approved for marketing or import.
Memantine is an excitatory amino acid receptor antagonist used in the treatment of moderate to severe Alzheimer's dement.
According to data from Min.
com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
Hospital Hospital Hospital Pharmacy Pharmacy PharmacyAccording to data from Min.
com, in 2021, the sales volume of Memantine will be more than 300 million yuan in China's urban public hospitals , county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions); while in the retail market ( Including Chinese urban physical pharmacy terminals and Chinese online pharmacy terminals, excluding county and rural physical pharmacies), Memantine's sales scale is also at the level of 100 million yu.
Figure 1: 2021 Memantine Sales Percentage in Various End Markets
Source: Mi intranet database
The terminals of public medical institutions in China are the main battlefield of Memanti.
Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
Affected by the price reduction of domestic procurement, the sales of tablets have declined sharply, while capsules and oral liquids have shown a rapid growth tre.
It can be seen that granules, as a non-centralized procurement method New dosage forms, the market potential is still promisi.
Table 1: Improved new drugs declared by Zhejiang Puli Pharmaceutical since 2020
Source: MED0 China Drug Evaluation Database
Levetiracetam granules are Puli's first improved new drug to be declared for marketi.
At present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
enterprise enterprise enterpriseAt present, only one company has reported for production, and there is a high probability that it will be the first in Chi.
In addition to the clinical application of memantine hydrochloride granules this time, the oxcarbazepine dry suspension that has been approved for clinical use earlier is also the first application of Puli, with obvious competitive advantag.
Judging from the current situation, Puli's improved new drugs are concentrated in the field of nervous syst.
Source: CDE official website, Minet database
